TD Cowen analyst Joseph Thome has maintained their bullish stance on ARWR stock, giving a Buy rating on August 6.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Thome has given his Buy rating due to a combination of factors, primarily focusing on Arrowhead Pharmaceuticals’ robust pipeline and promising late-stage developments. The company’s candidate, Plozasiran, is on track for an NDA review with a PDUFA date set for November 18, and both management and key opinion leaders are optimistic about its approval due to positive Phase III data.
Additionally, the company is making significant strides in its Phase III trials for Plozasiran targeting sHTG, a condition with a substantially larger market opportunity compared to FCS. Arrowhead Pharmaceuticals is also advancing its obesity candidates, with initial data expected by the end of the year. These developments, along with the potential for Zodasiran in HofH and future plans for ARO-MAPT in Alzheimer’s, contribute to the positive outlook and Buy rating from Joseph Thome.
In another report released on August 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.